AbbVie

Senior Scientist I/II – DMPK, CYP metabolism and DDI

Posted on: 22 Jan 2021

Chicago, IL

Job Description

About AbbVie
AbbVies mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on peoples lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, womens health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

AbbVie is seeking a highly motivated and experienced scientist to join our Drug Metabolism and Pharmacokinetics team in North Chicago. The ideal candidate will have strong background and expertise with in vitro drug metabolism, drug-drug interactions and biotransformation enzymology. Applicants having experience in an adjacent area, such as drug transport and pharmacokinetic modeling is desirable. In this exciting role, you will be expected to participate in implementing innovative and quantitative approaches to advance translational ADME. The position will involve the conduct and scientific leadership of in vitro assays as well as applying translational modeling concepts to drive the global in vitro ADME strategy at AbbVie. You will be expected to evaluate new technologies and approaches to support the mechanistic and translational understanding of metabolism and drug-drug interactions. In addition, you will have opportunities to contribute to broader areas within DMPK as your experience and expertise warrants.

Core responsibilities include:

* Designing and conducting custom in vitro ADME assays and generating high quality, impactful data that enables decision-making
* Applying translational modeling concepts for small molecules to enable human PK and DDI projections
* Evaluating novel in vitro tools and methods to enable and improve prediction of human PK
* Liaise with DMPK, discovery biology/pharmacology and clinical scientists to generate data and knowledge supporting the build-up of translational, mechanistic models
* Ability to clearly communicate internally and externally on topics related to in vitro drug metabolism
* Keep up to date with emerging literature and science in modeling and in vitro approaches
* Serve as a leader, coach and manager of bench scientists

Qualifications
Basic Qualifications:

* PhD degree Biological/Pharmaceutical Sciences/Chemistry or related field with 0-10 years of relevant ADME pharma/biotech industry experience; or a Bachelors/Masters degree with > 10 years experience with in vitro ADME experiments and DMPK projects, through academic or industry work.
* Deep understanding of drug metabolism and ADME principles including enzyme kinetics, IVIVE and DDI risk assessment
* Strong and relevant publication record as well as a track record of strategic scientific leadership in the in vitro ADME field
* Highly motivated, self-driven and results-oriented person with excellent communication and presentation skills, capable to work both as team player and independent scientific contributor
* Passion for data analysis, solving technical problems and applying new technologies to further scientific goals.

Key Leadership Competencies:

* Builds strong relationships with peers and cross functionally with partners outside of team to enable higher performance
* Ability to inspire and lead others in areas of your expertise
* Learns fast, grasps the essence and can change course quickly where indicated
* Raises the bar and is never satisfied with the status quo
* Creates a learning environment, open to suggestions and experimentation for improvement
* Embraces the ideas of others, nurtures innovation and manages innovation to reality

Significant Work Activities
Continuous sitting for prolonged periods (more than 2 consecutive hours in an 8 hour day)
Travel
No
Job Type
Experienced
Schedule
Full-time
Job Level Code
M
Equal Employment Opportunity
At AbbVie, we value bringing together individuals from diverse backgrounds to develop new and innovative solutions for patients. As an equal opportunity employer we do not discriminate on the basis of race, color, religion, national origin, age, sex (including pregnancy), physical or mental disability, medical condition, genetic information gender identity or expression, sexual orientation, marital status, protected veteran status, or any other legally protected characteristic.

AbbVie

Chicago, IL

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström’s macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia.

Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Similar Jobs